Carisma Therapeutics Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Expanded clinical manufacturing capacity through successful technology transfer of CT-0508  Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol "CARM" PHILADELPHIA , May 11, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights. "In the first quarter, we closed our merger with Sesen Bio, Inc., which further strengthened our foundation to advance our pipeline through the end of 2024," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York. A live webcast will be available on the Company's Investor Events webpage and you can also register to view the webcast for the JMP Securities Life Sciences Conference here.

Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference

PHILADELPHIA , May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at several healthcare industry conferences in May 2023. These conferences include: American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting 2023 Carisma is giving an oral presentation during the meeting: Chris Sloas, Ph.D.

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

PHILADELPHIA, April 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting held from Friday, April 14 – Wednesday, April 19 in Orlando, FL. The accepted data reinforce the potential of Carisma's differentiated and proprietary cell therapy platform focused on engineered macrophages as a novel treatment pathway for hard-to-treat cancers and other serious illnesses.

Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting

PHILADELPHIA , April 6, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023. Upcoming healthcare industry conferences include: 2023 Cell & Gene Meeting on the Med Tom Wilton, Chief Business Officer, will give a corporate presentation.

Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023

Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol "CARM" Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through 2024 PHILADELPHIA , April 4, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the year ended December 31, 2022 and highlighted recent business updates. "2022 was a transformational year for Carisma as we made meaningful progress across all areas of our business, including entering a development collaboration with Moderna, advancing our lead program CT-0508 in HER2+ solid tumors, and announcing our merger with Sesen Bio," said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights

News for Carisma Therapeutics Inc Stock (CARM)